MedPharm moves into $4M expansion of its North Carolina facility
Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.
MedPharm, experts in topical and transdermal drug delivery, has moved into its newly expanded facility in Durham, North Carolina.
The $4-million expansion has tripled the facility’s footprint to approximately 25,000 sq. ft significantly expanding capacity and supporting MedPharm’s continued commitment to the topical and transdermal market.
Investment into the site was made following increased demand for MedPharm’s topical and transdermal services. The expansion covers pre-formulation and formulation development, in vitro release, in vitro penetration/permeation, tissue culture, analytical/bioanalysis, custom device development and tissue engineering. In addition, the new space will include dedicated innovation, microbiology and histology laboratories.
“We are excited to be able to offer an expanded and unmatched level of services from our facility in the North Carolina Research Triangle Park area”, commented Eugene Ciolfi MedPharm’s President and CEO. “The expanded space has a streamlined workflow that segregates phases of work and makes transition through each project more efficient with complimentary equipment positioned where it’s most needed.”
The new laboratory expands capacity for MedPharm’s proprietary models which de-risk its customers’ development programs as it accommodates automated and high throughput analytical instrumentation to improve turnaround times and elevate the consistent quality of data for clients.
The facility’s unique, dedicated innovation Lab will allow MedPharm to continue its pioneering approach to the development of custom performance testing models to meet unmet customer needs in the topical and transdermal markets. This investment also means that MedPharm can react quickly to solving project-specific problems for its customers and stay at the forefront of the latest scientific breakthroughs and technology.
The expansion will also create over 100 new highly skilled scientific and strategic positions in Research Triangle Park in North Carolina.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.